CADL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Candel Therapeutics Inc (CADL) is not a strong buy at this moment for a beginner investor with a long-term strategy. While there is positive analyst sentiment and a promising pipeline, the lack of significant financial growth, absence of strong trading signals, and neutral insider/hedge fund activity suggest holding off on immediate investment.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 69.107, and moving averages are converging, showing no clear trend. The stock is trading near resistance levels (R1: 5.154, R2: 5.263), which may limit short-term upside.
and a higher probability of success for aglatimagene in lung cancer trials. The company is progressing with its lung cancer trial and prostate launch plans.
No recent news or congress trading data. Financials show no revenue and significant net losses (-$29.5M in Q4 2025). Stock trend analysis predicts a potential short-term decline (-0.94% next day, -2% next week).
In Q4 2025, revenue remained at $0, net income improved YoY to -$29.5M (+109.59%), and EPS improved to -0.54 (+35%). However, the company is still unprofitable with no revenue growth.
Citi maintains a Buy rating with a raised price target of $26, citing promising trial data and increased probability of success for its lead drug candidate. However, dilution concerns led to a previous price target cut.
